Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F17%3A10360797" target="_blank" >RIV/00216208:11110/17:10360797 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.msard.2016.11.005" target="_blank" >http://dx.doi.org/10.1016/j.msard.2016.11.005</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.msard.2016.11.005" target="_blank" >10.1016/j.msard.2016.11.005</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis

Popis výsledku v původním jazyce

Background: Patient-reported outcomes (PROs) provide information on treatment effects from the patient&apos;s perspective that complement outcomes on clinical measures. In DECIDE, daclizumab demonstrated superior efficacy in reducing relapses, 24-week confirmed disability progression, and brain lesions (assessed by magnetic resonance imaging [MRI]) versus intramuscular interferon beta-la in relapsing-remitting multiple sclerosis. Objective: To examine the impact of daclizumab versus interferon beta-la on PROs in DECIDE. Methods: DECIDE was a randomized, double-blind, active-controlled, phase 3 study comparing daclizumab 150 mg subcutaneous every 4 weeks with interferon beta-1a 30 mcg intramuscular once weekly. The 29-item Multiple Sclerosis Impact Scale (MSIS-29) and EuroQoL 5-Dimensions (EQ-5D) were assessed at baseline and every 24 weeks. Mean changes from baseline were analyzed using analysis of covariance models. Individual items for the MSIS-29 physical (PHYS) and psychological (PSYCH) subscales were analyzed post hoc. Results: Daclizumab treatment resulted in greater mean improVements relative to baseline in MSIS-29 PHYS and PSYCH scores starting at week 24 that persisted over 96 weeks. Mean improvements from baseline in MSIS-29 PHYS and PSYCH scores were significantly greater for daclizumab versus intramuscular interferon beta-la at week 96. Daclizumab-treated patients showed steady improvements in EQ-5D health utility index and EQ-5D visual analog scale scores over the study period, with significantly greater improvements versus intramuscular interferon beta-la at week 96 (p=0.0048 and p=0.0006, respectively). Conclusions: Improvements in patient-reported physical and psychological functioning and general health status with daclizumab compared with intramuscular interferon beta-la are consistent with outcomes on clinical and brain MRI lesion measures in DECIDE (NCT01064401).

Název v anglickém jazyce

Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis

Popis výsledku anglicky

Background: Patient-reported outcomes (PROs) provide information on treatment effects from the patient&apos;s perspective that complement outcomes on clinical measures. In DECIDE, daclizumab demonstrated superior efficacy in reducing relapses, 24-week confirmed disability progression, and brain lesions (assessed by magnetic resonance imaging [MRI]) versus intramuscular interferon beta-la in relapsing-remitting multiple sclerosis. Objective: To examine the impact of daclizumab versus interferon beta-la on PROs in DECIDE. Methods: DECIDE was a randomized, double-blind, active-controlled, phase 3 study comparing daclizumab 150 mg subcutaneous every 4 weeks with interferon beta-1a 30 mcg intramuscular once weekly. The 29-item Multiple Sclerosis Impact Scale (MSIS-29) and EuroQoL 5-Dimensions (EQ-5D) were assessed at baseline and every 24 weeks. Mean changes from baseline were analyzed using analysis of covariance models. Individual items for the MSIS-29 physical (PHYS) and psychological (PSYCH) subscales were analyzed post hoc. Results: Daclizumab treatment resulted in greater mean improVements relative to baseline in MSIS-29 PHYS and PSYCH scores starting at week 24 that persisted over 96 weeks. Mean improvements from baseline in MSIS-29 PHYS and PSYCH scores were significantly greater for daclizumab versus intramuscular interferon beta-la at week 96. Daclizumab-treated patients showed steady improvements in EQ-5D health utility index and EQ-5D visual analog scale scores over the study period, with significantly greater improvements versus intramuscular interferon beta-la at week 96 (p=0.0048 and p=0.0006, respectively). Conclusions: Improvements in patient-reported physical and psychological functioning and general health status with daclizumab compared with intramuscular interferon beta-la are consistent with outcomes on clinical and brain MRI lesion measures in DECIDE (NCT01064401).

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30103 - Neurosciences (including psychophysiology)

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Multiple Sclerosis and Related Disorders

ISSN

2211-0348

e-ISSN

—

Svazek periodika

11

Číslo periodika v rámci svazku

January

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

7

Strana od-do

18-24

Kód UT WoS článku

000394068700006

EID výsledku v databázi Scopus

2-s2.0-84996605876